CRO in China: SWOT Analysis and Development Strategies

Asina Journal Of Social Pharmacy

Previous Articles Next Articles

CRO in China: SWOT Analysis and Development Strategies

Ding Ling, Dong Li*

School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

Online:2018-09-20 Published:2018-11-13
Contact: Dong Li, associate professor and master tutor. Main research area: pharmaceutical intellectual property and international trade in medicine. Tel: 024-23986543, E-mail: sydongli@163.com.

Abstract

Ding Ling, Dong Li. CRO in China: SWOT Analysis and Development Strategies[J]. Asina Journal Of Social Pharmacy.

Trendmd

[1]	Shi Jiatong, Sun Lihua. Research on the Joint Reformation for Public Health Services, Medical Insurance and Medical Production Circulation from the Perspective of System Science [J]. Asian Journal of Social Pharmacy, 2024, 19(3): 209-215.
[2]	Zhang Yuanyuan, Tian Lijuan. The Development and Experience of American Pharmaceutical Industry Associations and Its Enlightenment to China [J]. Asian Journal of Social Pharmacy, 2024, 19(3): 237-243.
[3]	Zhao Meng, Huang Zhe. Comparison of the Development of CDMO at Home and Abroad and Its Enlightment to China [J]. Asian Journal of Social Pharmacy, 2024, 19(3): 244-250.
[4]	Wang Mingzheng, Wang Shuling. Suggestions on the Good Development of Pharmaceutical Cold Chain Logistics in China [J]. Asian Journal of Social Pharmacy, 2024, 19(3): 263-271.
[5]	Diao Yuanyuan, Wu Zhiang. Identifying and Managing Technical Risks in the Process of Innovative Drugs Development in China [J]. Asian Journal of Social Pharmacy, 2024, 19(2): 126-134.
[6]	Li Yanli, Huang Zhe. Comparison of the Development Model of DTP Pharmacy between China and the United States and Its Enlightenment [J]. Asian Journal of Social Pharmacy, 2024, 19(2): 168-177.
[7]	Song Yamei. Study on the Changes of Medical Income Structure in Government-run Hospitals of Traditional Chinese Medicine from 2012 to 2021 [J]. Asian Journal of Social Pharmacy, 2024, 19(2): 178-190.
[8]	Sun Yuyuan, Wang Shuling. Countermeasures and Suggestions for Strengthening Human Resource Management in China’s Pharmaceutical Industry [J]. Asian Journal of Social Pharmacy, 2024, 19(2): 202-207.
[9]	Diao Yuanyuan, Wu Zhiang. Analytic Hierarchy Process for Technological Risks in the Process of Innovative Drug Development in China [J]. Asian Journal of Social Pharmacy, 2024, 19(1): 29-42.
[10]	Wang Jianing, Wang Shuling. Research on the Status Quo and Countermeasures of Human Resource Management Outsourcing in China’s Pharmaceutical Enterprises [J]. Asian Journal of Social Pharmacy, 2024, 19(1): 64-71.
[11]	Gao Lin, Sun Lihua. An Exploration of Organizational Development in the Process of Innovation and Transformation of Pharmaceutical Enterprises - Taking X Pharmaceutical Enterprise as an Example [J]. Asian Journal of Social Pharmacy, 2024, 19(1): 72-80.
[12]	Teng Xinyi, Tian Lijuan. The Status Quo and Enlightenment of the Foreign Extended Clinical Trial System [J]. Asian Journal of Social Pharmacy, 2023, 18(4): 335-344.
[13]	Xiu Yu, Wang Shuling. Investigation and Countermeasures of the Development of Chinese Pharmaceutical E-commerce in the B2C Model Based on PEST-SWOT Analysis [J]. Asian Journal of Social Pharmacy, 2023, 18(4): 398-405.
[14]	Zhang Zongjie, Wu Zhiang. Research on the Countermeasures for the Development of Biopharmaceutical Industrial Parks in China [J]. Asian Journal of Social Pharmacy, 2023, 18(3): 232-238.
[15]	Guo Jialin, Wang Shuling. Exploration and Research on the Integrated Development of “Internet Plus Medical Treatment” [J]. Asian Journal of Social Pharmacy, 2023, 18(3): 252-260.

Asian Journal Of Social Pharmacy

CRO in China: SWOT Analysis and Development Strategies

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments